PRINCETON, N.J.--(BUSINESS WIRE)--Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.
“The responsiveness and insightful guidance from the FDA have been helpful in solidifying our decision to move forward with building Braeburn’s strong focus in addiction medicine,” said Behshad Sheldon, President and Chief Executive Officer of Braeburn Pharmaceuticals. “We are keen to begin the new trial for Probuphine, which if approved should lay a strong foundation for our company.”
Help employers find you! Check out all the jobs and post your resume.
